nPhase, a US-based clinical research technology company, has raised $30 million in a Series D funding round led by Viking Global Investors. Announced on November 2, 2026, the financing will support the expansion of the company’s AI-native clinical data platform and the development of automated workflows for pharmaceutical research.
The investment marks nPhase’s first equity fundraising round since 2017. The company plans to use the capital to expand its enterprise clinical data operations, strengthen its statistical computing capabilities and develop agentic AI applications across the clinical research lifecycle.
Based in Atlantic Beach, Florida, nPhase develops software designed to help pharmaceutical companies and contract research organisations (CROs) manage, process and analyse clinical trial data.
Its nPhase.ai platform, launched in September 2026, integrates two core systems: the Unified Data Management System (UDMS) and the Statistical Computing Environment (SCE).
UDMS brings together clinical information from research sites, laboratories, patients and digital health devices into a centralised environment. The system supports data standardisation, validation and monitoring throughout clinical studies.
SCE supports statistical programming, dataset preparation and the production of analytical outputs required for regulatory submissions. Together, the systems are designed to connect clinical data collection, analysis and submission preparation within a single platform.
Led by CEO Scott Climes, nPhase plans to expand its use of AI agents for operational tasks, including identifying data discrepancies and assisting with statistical programming. The company says these capabilities are intended to reduce manual processing while keeping clinical research professionals responsible for critical decisions.
Alongside nPhase.ai, the company operates REDCap Cloud, an electronic data capture platform serving pharmaceutical and biotechnology companies, academic institutions, nonprofit research organisations, medical technology studies and real-world data programmes.
The Series D financing will support further development of nPhase’s clinical data infrastructure and its AI-enabled tools for managing clinical research workflows.

